Chardan Capital Markets analyst Keay Nakae reiterated a Buy rating and $60.00 price target on Arrowhead Pharma (NASDAQ: ARWR)The analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments

Arrowhead Pharma (ARWR) PT Lowered to $41 at BofA SecuritiesFebruary 11, 2025 5:22 AM Form 4 ARROWHEAD PHARMACEUTICAL For: Feb 07 Filed by: Anzalone Christopher RichardFebruary 10, 2025 6:23 PM Form 10-Q ARROWHEAD PHARMACEUTICAL For: Dec 31February 10, 2025 4:04 PM Form 8-K ARROWHEAD PHARMACEUTICAL For: Feb 10February 10, 2025 4:04 PM Arrowhead Pharmaceuticals Inc. (ARWR) Misses Q1 EPS by 100cFebruary 10, 2025 4:03 PM Arrowhead Pharmaceuticals Reports Fiscal 2025 First Quarter ResultsFebruary 10, 2025 4:01 PM Arrowhead Pharmaceuticals (ARWR) Announces Closing of Global License and Collaboration Agreement with Sarepta Therapeutics (SRPT)February 10, 2025 8:31 AM Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Sarepta TherapeuticsFebruary 10, 2025 8:30 AM Form 4 ARROWHEAD PHARMACEUTICAL For: Feb 06 Filed by: INGRAM DOUGLAS SFebruary 7, 2025 5:58 PM Form 3 ARROWHEAD PHARMACEUTICAL For: Feb 06 Filed by: INGRAM DOUGLAS SFebruary 7, 2025 5:57 PM Form 8-K ARROWHEAD PHARMACEUTICAL For: Feb 07February 7, 2025 6:01 AM Form DEFA14A ARROWHEAD PHARMACEUTICAL February 7, 2025 6:01 AM